• Large-scale Collaborative Effort Aims to Increase Understanding of Cancer Therapy Combinations
  • Presage Biosciences Awarded Grant to Develop CIVO Microdosing Platform Used Inside Tumors
  • Imlygic-Yervoy Combo Twice as Effective as Yervoy in Fighting Melanoma, Study Finds
  • Microsatellite Stable Colorectal Cancer Dosing Begins in Phase 2 Trial of Combo Therapy
  • EMA to Review Marketing Application for Imfinzi as NSCLC Treatment
  • SELLAS and Merck Plan Phase 1/2 Trial of Galinpepimut-S and Keytruda in Five Cancers
  • FDA Approves Quicker L-DOS47 Dose Escalation in Phase 1 Lung Cancer Trial
  • MD Anderson Cancer Center, Pfizer to Jointly Investigate Therapies for Blood Cancers, Solid Tumors
  • First Clinical Trial Testing NBTXR3 Plus Immune Checkpoint Inhibitors to Recruit Patients in the US
  • Selexis, OSE Team Up to Advance Two Cancer Immunotherapy Programs
  • Researchers Develop Guidelines for Management of CAR T-cell Triggered Toxicities
  • IMO-2125, Yervoy Combo Shows Promise in Preclinical Data and Phase 1 Studies